How Serious Are Diagnostic Players About Alliances? Not Very.
As a proxy for seriousness in diagnostics alliances, we decided to use equity investments, which, in pharmaceutical alliances at least, often correlate with the depth of interest the funding partner has in its technology partner's program.
You may also be interested in...
ABHI’s Phil Brown looks beyond the immediate challenges for UK medtechs on being outside the EU, and to an innovation-friendly, patient-responsive system of future regulation.
For a biotech launching its first product the pandemic has compounded the usual pressures of a competitive indication against deeper-pocketed competition.
Following Mylan’s initial launch of a generic rival to Biogen’s $3.8bn Tecfidera brand, other generics companies are now following the firm into the US dimethyl fumarate market.